Pipeline


ONCOLOGY
ARQ 197	C-Met Inhibitor	Daiichi Sankyo⁴ Kyowa Hakko⁵
ARQ 501	E2F1 Pathway Activator
ARQ 761	E2F1 Pathway Activator
ARQ 621	Eg5 Inhibitor
BRAF Kinase Inhibitor
Selective, ATP-exclusionary Kinase Inhibitors	Arqule Kinase Inhibitor Platform (AKIP^TM)	Daiichi Sankyo⁶ and Internal Program
NON-ONCOLOGY ArQule has provided compounds to certain pharmaceutical companies that are pursuing development programs in non-oncology indications. As material information becomes available regarding the status of these programs, ArQule will provide updates through its press releases or filings. Portfolio Updated July 2008 ¹ Pre-GLP toxicology testing ² Post-initation of GLP toxicology testing ³ Designation follows initation of first patient enrollment and dosing ⁴ U.S., Europe, South America and the rest of the world, excluding Japan and select Asian countries ⁵ Japan and select Asian countries ⁶ Two targets in oncology; other applications for additional collaborations under consideration